Guelph, ON—Nutrasource Pharmaceutical and Nutraceutical Services announced that GRAS Associates, a fully owned subsidiary of Nutrasource, has successfully submitted a GRAS Notice to the FDA on behalf of Nascent Health Sciences‘ sweetener extract.
“GRAS Associates is pleased to have assisted Nascent Health Sciences in realizing their goals of GRAS status and FDA ‘no questions’ for the GRAS notification (GRN 983) of their SoPure purified steviol glycosides,” shared Amy Mozingo, Vice President of US Nutra Regulatory Sciences, Nutrasource/GRAS Associates, in a press release. “Our scientific team is uniquely positioned to provide expert guidance for achieving GRAS status for steviol glycosides ingredients as over half of the GRAS conclusion notified to FDA have been successfully submitted by GRAS Associates.”
Hank Wang, Technical Director of Nascent Health Sciences, added: “This confirmation expands upon the FDA’s previous No Objection for our Reb A to now include all steviol glycosides we extract from the leaf. This now provides our manufacturing customers with confidence knowing that their stevia supply is not only grown naturally and sourced sustainably, but is also safe and backed by the most stringent regulatory approvals.”
Related: Nutrasource Announces Reception of Patent for IGEN Program
The Natural View: Talking Certifications & Amazon Compliance
The release notes that SoPure Stevia is used in a range of products, including beverages, baked goods and desserts, condiments and sauces, confections, dairy products, tabletop sweeteners, and personal care products such as cosmetics, toothpaste, dietary supplements and more.
“Nutrasource/GRAS Associates was an essential partner in securing the FDA review and confirmation,” Wang said. “Their expertise was evident throughout the process as they guided us towards the successful conclusion by the FDA.”